Bonk (NASDAQ:BNKK) Director Mitchell Austin Rudy Acquires 31,055 Shares

Bonk, Inc. (NASDAQ:BNKK) Director Mitchell Austin Rudy purchased 31,055 shares of the company’s stock in a transaction dated Thursday, April 9th. The stock was purchased at an average cost of $2.82 per share, for a total transaction of $87,575.10. Following the transaction, the director owned 44,198 shares of the company’s stock, valued at approximately $124,638.36. This trade represents a 236.29% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Bonk Stock Performance

Shares of Bonk stock opened at $2.75 on Friday. The business has a fifty day moving average of $3.10. The firm has a market capitalization of $21.59 million, a P/E ratio of -0.36 and a beta of 2.10. Bonk, Inc. has a 1 year low of $2.29 and a 1 year high of $46.90.

Bonk (NASDAQ:BNKK) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($8.27) earnings per share (EPS) for the quarter. The company had revenue of $1.82 million during the quarter. Bonk had a negative return on equity of 208.29% and a negative net margin of 1,993.19%.

Institutional Investors Weigh In On Bonk

Several hedge funds and other institutional investors have recently modified their holdings of BNKK. State Street Corp acquired a new stake in shares of Bonk in the fourth quarter worth $33,000. Steward Partners Investment Advisory LLC acquired a new stake in Bonk during the fourth quarter worth $37,000. Jane Street Group LLC acquired a new stake in Bonk during the fourth quarter worth $96,000. Finally, Geode Capital Management LLC acquired a new stake in Bonk during the fourth quarter worth $128,000. Institutional investors and hedge funds own 12.55% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Bonk in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Bonk Company Profile

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.